Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of subcutaneous tocilizumab in moderate to severe rheumatoid arthritis
2012-002632-87Phase 3Completed
- Sponsor
- Roche Farma, S.A.
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of tocilizumab in rheumatoid arthritis (RA) (2 cohorts), sponsored by Roche Farma, S.A. Primary endpoint: Safety outcomes. Started Aug 2012; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-002632-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002632-87.